Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 5/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | HTR7 | P34969 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | BLM | P54132 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metaterol SCHEMBL10614404 | 0.98 | HIF1A (0.71) | HIF1AADRB2TSHRADRB1ADRA1A | |
| Metaproterenol SCHEMBL1679992 | 0.90 | ADRB2 (0.75) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL4625692 | 0.85 | ADRB2 (0.64) | HIF1AADRB2TSHRADRB1ADRA1A | |
| Metaproterenol SCHEMBL15163491 | 0.83 | ADRB2 (0.67) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL31676604 | 0.83 | HIF1A (0.61) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL22362712 | 0.83 | HIF1A (0.61) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL20819520 | 0.83 | HIF1A (0.61) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL20819521 | 0.83 | HIF1A (0.61) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL31676571 | 0.83 | HIF1A (0.61) | HIF1AADRB2TSHRADRB1ADRA1A | |
| SCHEMBL19329958 | 0.83 | HIF1A (0.61) | HIF1AADRB2TSHRADRB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4407819-A | ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1983-10-04 | — | — | US | claimed |
| CN-114057590-A | Synthetic method of key intermediate of odaterol | 安徽有吉医药科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | THE UNIVERSITY OF TULSA (US) | 2022-02-03 | — | — | US | disclosed |
| CN-111574529-A | Muscarinic receptor M3 antagonists and β 2-adrenergic receptor agonist bridged ring derivatives | 四川海思科制药有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| EP-2401275-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | Respiratorius AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| US-4754047-A | ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1988-06-28 | — | — | US | disclosed |
| US-4522822-A | Phenylethane derivatives and acid addition salts thereof for increasing lean meat deposition and/or improving lean meat to fat ratio in warm blooded animals | AMERICAN CYANAMID COMPANY (US) | 1985-06-11 | — | — | US | disclosed |
| US-4501751-A | Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby | AMERICAN CYANAMID COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| EP-0026298-B1 | METHOD FOR PROMOTING GROWTH AND REDUCING FAT IN ANIMALS USING PHENYLETHANOLAMINE DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1984-04-18 | — | — | EP | disclosed |
| US-4407819-A | ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4404222-A | Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby | AMERICAN CYANAMID COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| EP-0026298-A1 | Method for promoting growth and reducing fat in animals using phenylethanolamine derivatives | AMERICAN CYANAMID COMPANY (US) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | HK2, G6PD, GCK | HIF1A 136/4885ADRB2 2308/4885TSHR 4647/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | HIF1A 907/4885ADRB2 5/4885TSHR 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.